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Background: Little is known regarding the demographic and behavioral characteristics of nonmedical prescription
drug users (NMPDUs) entering substance abuse treatment settings, and information on the HIV-related risk profiles
of NMPDUs is especially lacking. Participation in substance abuse treatment provides a critical opportunity for
HIV prevention and intervention, but successful initiatives will require services appropriately tailored for the needs
of NMPDUs.
Methods: This paper compares the HIV risk profiles of NMPDUs in public (n = 246) and private (n = 249) treatment
facilities. Participants included in the analysis reported five or more recent episodes of nonmedical prescription drug use,
a prior HIV negative test result, and current enrollment in a substance abuse treatment facility. A standardized
questionnaire was administered by trained interviewers with questions about demographics, HIV risk, and substance use.
Results: Private treatment clients were more likely to be non-Hispanic White, younger, and opioid and heroin users.
Injection drug use was higher among private treatment clients, whereas public clients reported higher likelihood of
trading or selling sex. Public treatment clients reported higher rates of HIV testing and availability at their treatment
facilities compared to private clients.
Conclusions: Findings suggest differing demographics, substance use patterns, profiles of HIV risk and access to HIV
testing between the two treatment samples. Population tailored HIV interventions, and increased access to HIV testing
in both public and private substance treatment centers, appear to be warranted.
Keywords: HIV, Substance treatment, Nonmedical prescription drug useBackground
Treatment of prescription drug abuse and dependence
The nonmedical use of prescription drugs (NMUPD) is
an escalating problem in the United States [1-3] and, by
population prevalence, appears to have overtaken most
illicit substances. NMUPD now exceeds all categories of
abused substances, with the exception of marijuana [4,5].
Two of the most commonly prescribed classes of prescrip-
tion drugs with abuse potential are benzodiazepines,
or central nervous system depressants, and opioids
[6]. Although benzodiazepines are typically prescribed* Correspondence: cogrady@nova.edu
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reproduction in any medium, provided the oras short term therapy for anxiety or sleep disorders [6]
and opioids are indicated to control acute or chronic
pain [6,7], many people use these medications in non-
medical ways or without a valid prescription. Long
term or nonmedical use of opioids or benzodiazepines,
such as taking larger doses of the medication, can re-
sult in tolerance and/or dependence [6,8]; large doses
of opioids, or combined use of opioids and another
depressant such as alcohol, can lead to respiratory de-
pression or death [6]. Moreover, combining benzodi-
azepines with other substances such as alcohol have
similar outcomes [6]. NMUPD results in more emergency
room visits than any illicit drug [3], and is involved in
more deaths than heroin or cocaine [3,8].l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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admission rates for primary use of opiates other than her-
oin have increased substantially from 2000 to 2010 across
the United States [9]. Despite the increasing prevalence of
nonmedical prescription drug users (NMPDUs) in sub-
stance abuse treatment facilities, the literature describing
these populations and the efficacy of treatment is sparse
[2,10]. Moreover, accurate estimates of the numbers of
NMPDUs in treatment facilities are not available due to a
lack of data characterizing specific prescription medication
use and a lack of studies that include both private and
public treatment facilities [11]. Health and social risk pro-
files of treatment seeking NMPDUs are needed, as these
individuals are likely to differ from other substance users
in terms of specific characteristics that could impact treat-
ment services needs, such as underlying medical condi-
tions and demographics [10,12-14].
HIV risk and NMPDU
A comprehensive profile of treatment-based NMPDUs
would include information on HIV behavioral risks, in-
cluding injection drug use and high risk sexual behav-
iors. Definitive information describing the injection of
prescription medications is lacking. Some studies have
found that injection drug use is more common among
users of certain prescription opioids such as morphine
[15,16] and extended release oxycodone [17,18]. Research
has also suggested that the injection of prescription medi-
cations is a result of a progression through other, more
conventional routes, and is therefore practiced by experi-
enced users [17-19]. Perhaps contradictorily, other studies
have associated younger age with a higher likelihood of
prescription opioid injection [17,19,20].
Sexual risk behaviors include sex without a condom,
trading or selling sex, sex with an injection drug user, or
having an elevated number of sex partners [21]. Although
the link between illicit drug use and increased sexual
behavior risk is well documented [21-25], there is less
information available about NMPDUs and increased sex-
ual risk. Among those misusing opioids and benzodiaz-
epines, studies have found associations with HIV sexual
risk among samples of undergraduate university students
[26], men who have sex with men [27,28] and oxycodone
users [29]. However, information on sexual HIV risk from
a large and diverse sample of NMPDUs is not apparent in
the literature.
Substance abuse treatment and HIV
Substance abuse treatment can impact HIV transmission
through reductions of both injection drug use [30] and
sexual risk behaviors [31]. As substance relapse is a
common phenomenon, enrollment in treatment often
represents a break from risky behaviors, providing an
opportunity to intervene [32]. For injection drug users,needle risk interventions include HIV education focusing
on behavioral skills and risk reduction, such as infor-
mation on using bleach solutions to clean needles [30]
or using syringe exchange programs [33]. Sexual risk
reduction interventions target both information about
HIV and relevant behavioral changes [31]. Testing for
HIV during treatment can also reach both injection
and non-injection substance users who are unaware of
their status [34].
The HIV risk behavior profiles of NMPDUs entering
substance abuse treatment have not been well documented.
Recent studies suggest that treatment seeking prescription
opioid abusers differ from heroin users in terms of demo-
graphic and drug use profiles [14] and indicate that sexual
risk behaviors are elevated among prescription opioid mis-
users entering detoxification treatment [29]. Given that the
number of treatment admissions is escalating at a national
level [9], characterizing the risk profiles and service needs
of this population assumes great importance.
In this regard, the primary goal of this paper is to
examine and compare the demographic and HIV-related
risk behavior profiles of NMPDUs in private and public
treatment facilities; public treatment centers are federally,
state and/or locally funded while private centers require
direct monetary payment or insurance coverage. The
funding source for treatment tends to impact client/
staff ratios, program size, as well as other key aspects
of the treatment environment [35]. Client profiles are
also likely to diverge, as many individuals in public
treatment centers are referred from the criminal justice
system, often paying small or sliding scale fees to attend
treatment [36], and presumably are without access to
private medical insurance or other financial resources.
Prior surveillance efforts have indicated that HIV testing
and prevention services tend to be more widely available
in publically-funded treatment programs when compared
with privately operated facilities [37,38]. Nevertheless,
there is little extant evidence to indicate that this differ-
ence reflects the actual risk profiles of the patients being
treated. As such, this paper sought to explore differences
in NMUPD patterns and HIV risk behavior profiles,
between private and public treatment clients for the pur-
poses of understanding whether existing HIV-related
services are appropriately matched to meet the needs
of the target populations. Background information,
demographics, social and HIV risk assessments are ne-
cessary for designing effective HIV interventions and
educational programs for this growing population of
treatment enrollees. By gaining an understanding of the
risk profiles of NMPDUs who present in different treat-
ment settings, researchers are equipped to assess the
adequacy of current HIV service levels and recommend
changes in treatment program policies related to access
and uptake of HIV testing and support services.
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Study sample
Eligible participants were age 18 or over and reported
five or more occasions of NMUPD within the 90 days
before entering substance treatment. The larger study
from which the sample was drawn (n = 1,629) included six
subgroups with different eligibility criteria: participants
aged 60 and older (n = 126), stimulant using men who
have sex with men (n = 300), methadone maintenance
clients (n = 301), street-based drug users (n = 301),
publically-funded residential treatment clients (n = 300)
and privately-funded residential treatment clients (n = 301).
For the current analysis, we included only public and
private treatment clients.
Study recruitment procedures varied by program accord-
ing to their internal policies. In some programs, partici-
pants were informed about the study by treatment staff,
either by center wide announcements or during intake as-
sessments. Eligibility screening was performed by treatment
staff, who informed the researchers of eligible interviewees.
In other programs, research staff were permitted to con-
duct the eligibility screening. All interested participants
were screened for eligibility to participate in this study. All
participants were assured that their participation in the
study was voluntary, and had no impact on their status in
their respective treatment programs.
Interviews took place in South Florida residential in-
patient treatment centers. Three public treatment centers
and three private treatment centers provided interviewees.
All treatment centers are well established and admit
between 350 to over 1000 clients per year. Following
informed consent, face to face confidential structured
interviews were conducted in private offices by trained
research staff. Interviews lasted about 1-1/2 to 2 hours.
After the completion of the interview, participants were
compensated with $30. Study protocols and instruments
were approved by the University of Delaware (prede-
cessor institution) and Nova Southeastern University
Institutional Review Boards, which follow the Helsinki
Declaration of 1975.Measures
The primary instrument was the Global Appraisal of
Individual Needs (GAIN-I) [39], an assessment tool that
contains measures of substance use and dependence and
sexual risk behaviors. The GAIN-I has been used regularly
in substance treatment research [40,41]. In our current
survey, questions about the nonmedical use of prescrip-
tion medications (opioids, benzodiazepines, stimulants,
antidepressants and antipsychotics) and routes of ad-
ministration were added. All substance use questions
used a 90 day recall period for days of misuse before
entering treatment.HIV sexual risk measures were assessed through di-
chotomous questions about behaviors within the past
12 months: having sex with an injection drug user, having
two or more sex partners, having unprotected sex, and
selling or trading sex. Measures for HIV needle risk were
dichotomous questions: a) in the past year, using a needle
to inject drugs, reusing a needle, and using someone else’s
rinse water, cooker or cotton; and b) in the past 90 days
before treatment entry, using a needle to inject a prescrip-
tion medication.
HIV testing availability in the treatment center was
measured by three yes or no questions. If a participant
answered “do not know” or “no” when asked if HIV testing
was available in the treatment facility, they were not asked
the subsequent questions: “have you been offered HIV
testing” and “did you participate in HIV testing”.
Data analysis
Participants who reported a positive HIV test (n = 16) or
who did not report a prior HIV test (n = 48) were elimi-
nated from the analysis in order to focus on the assessment
of HIV infection risk and access to HIV testing among
seronegative individuals.
Primary prescription drug was calculated by determin-
ing the medication that the participants reported misusing
on the greatest number of days in the 90 days prior to
treatment. Primary drug class (opioid or benzodiazepine)
was determined by the class of drug used the greatest
number of days in the 90 days prior to treatment. Only
participants that had a clear primary drug class (opioid or
benzodiazepine (n = 495; exclusions = 42)) were included
in this analysis.
All analyses were conducted using SPSS version 20.
Descriptive statistics characterized the overall profile of
the sample and the public and private treatment groups
separately. These measures included age, gender, income,
education, race/ethnicity, health insurance status and pri-
mary prescription substance of misuse.
Bivariate logistic regression models were constructed
to examine associations between treatment venue type,
demographics and sexual and needle HIV risks and ac-
cess and uptake of HIV testing. Private treatment clients
were the reference group for all analyses. Participants
were excluded from specific analyses if data were miss-
ing or the participant did not answer. The Ns for each
analysis are included in Table 1.
Results
Comparisons of public and private treatment participants
are reported in Table 1. Participants were currently enrolled
either in public (n =246/495; 49.7%) or private (n =249/495;
50.3%) substance treatment facilities. Public treatment
clients were more likely to identify as Latino/Hispanic
(41.1% vs. 7.2%) or Black/African-American (17.1% vs.
Table 1 Public and private treatment clients’ demographics, substance use characteristics, HIV risk behaviors and
testing availability
Private (n = 249) Public (n = 246) Wald OR (95% CI) p-value
n(%) n(%)
Demographics
Age (under 30 yrs) 162 (65.1) 109 (44.3) 21.18 0.43 (0.30, 0.61) <0.01
Female gender 97 (38.9) 104 (42.3) 0.57 1.15 (0.80,1.64) 0.45
Has medical insurancea 175 (70.6) 76 (31.3) 71.60 0.19 (0.13, 0.28) <0.01
Graduated high school 165 (66.3) 114 (46.3) 19.68 0.44 (0.31, 0.63) <0.01
Income $1000 or less in the last montha 73 (30.5) 126 (53.8) 25.79 2.65 (1.82, 3.87) <0.01
Lifetime arrests, mean (sd) 4.01 (7.35) 9.00 (11.29) 27.83 1.09(1.05, 1.12) <0.01
Race/Ethnicity <0.01
Non-hispanic white 207 (83.1) 90 (36.6) 99.68 0.12 (0.08, 0.18) <0.01
Non-hispanic black/ African-American 10 (4.0) 42 (17.1) 19.11 4.92 (2.41, 10.05) <0.01
Hispanic/Latino 18 (7.2) 101 (41.1) 62.57 8.94 (5.19, 15.38) <0.01
Other ethnicity 14 (5.6) 13 (5.3) 0.03 0.94 (0.43, 2.04) 0.87
Primary drug class
Opioids 199 (79.9) 131 (53.3) 37.85 0.29 (0.19, 0.43) <0.01
Benzodiazepines 50 (20.1) 115 (46.7) 37.85 3.49 (2.35, 5.21) <0.01
Other substances used
Crack cocaine 84 (33.7) 127 (51.6) 16.00 2.10 (1.46, 3.01) <0.01
Powder cocaine 135 (54.2) 153 (62.2) 3.23 1.39 (0.97, 1.99) 0.07
Heroin 82 (32.9) 41 (16.7) 17.00 0.41 (0.27, 0.62) <0.01
Routes of administration (90 days before treatment)
Injected pillsb 88 (35.3) 42 (18.8) 15.65 0.43 (0.28, 0.65) <0.01
Smoked pillsb 73 (29.3) 42 (18.8) 6.93 0.56 (0.36, 0.86) 0.01
Snorted pillsb 175 (70.3) 112 (50.2) 19.52 0.43 (0.29, 0.62) <0.01
Needle risk (past year)
Injected a drug 107 (42.9) 56 (22.8) 22.30 0.39 (0.27, 0.58) <0.01
Reused someone’s needlec 36 (33.6) 26 (46.4) 2.53 1.71 (0.88, 3.31) 0.11
Using someone else’s rinse water, cooker or cottona,c 33 (30.8) 24 (43.6) 2.58 1.74 (0.89, 3.40) 0.11
HIV sexual risk behaviors (year before treatment)
Sex with an injection drug usera,d 55 (23.1) 36 (15.9) 3.84 0.63 (0.39, 1.00) 0.05
Traded or sold sexd 32 (13.4) 63 (27.4) 13.74 2.38 (1.46, 3.81) <0.01
Two or more recent sexual partnersd 143 (59.8) 148 (64.3) 1.01 1.21 (0.83, 1.76) 0.31
Had sex without a condom or barriera,d 214 (90.3) 186 (80.9) 8.16 0.45 (0.26, 0.78) <0.01
HIV testing is available to you in this programa 117 (79.1) 199 (95.7) 19.92 5.86 (2.69, 12.74) <0.01
Has been offered HIV testing since arrivala,g 64 (55.7) 148 (75.1) 12.36 2.41 (1.48, 3.93) <0.01
Participated in HIV testing at this programa,g 27 (24.3) 117 (60.6) 34.73 4.79 (2.85, 8.06) <0.01
Note. Private treatment is the reference group. Df =1 for all. aParticipants were excluded that did not answer or answered “do not know”. bEarly initiates into the
study were not included (n = 23). cParticipants who had not injected a drug within the last twelve months were not included. dParticipants who had not had sex
within the last twelve months were not included (n = 26). gOnly participants who answered “yes” to the question, “is HIV testing available to you in this program”
were included.
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treatment clients, see Table 1) than their private treatment
counterparts. Public treatment clients had been arrested
more often than private treatment clients (9 vs. 4 times,
see Table 1). More private treatment clients identifiedas non-Hispanic White (83.1% vs. 36.6%, see Table 1) and
reported having health insurance than public treatment
clients (70.6% vs. 31.3%, see Table 1). Participants enrolled
in public treatment centers reported lower incomes, with
53.8% earning $1000 or less in the past month, compared
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were less likely to have graduated high school (46.3% vs.
66.3%, see Table 1). The gender breakdown was similar
among both private (38.9% female) and public (42.3%
female) treatment groups (see Table 1).
Public and private treatment clients differed significantly
on the primary prescription drugs that they used most
often for nonmedical purposes. Public treatment clients
were more likely (46.7%) than private (20.1%) clients to
report primary use of benzodiazepines (see Table 1), while
primary use of opioids was less likely among public treat-
ment clients (53.3% vs. 79.9%, see Table 1).
Many participants also used illicit substances in addition
to misusing prescription medication. The two groups
displayed significant differences in the types of substances
endorsed. Public treatment clients were more likely to re-
port use of crack cocaine in the 90 days before treatment
entry (51.6% vs. 33.7%, see Table 1). Clients who used
heroin in the 90 days before treatment were less likely
to be enrolled in public treatment clinics (16.7% in public
treatment vs. 32.9% in private treatment, see Table 1).
HIV risk behaviors were prevalent among the entire
sample, however public and private treatment clients
differed on several HIV risk measures. The treatment
groups did not differ in the number of recent sex partners
or the likelihood of having a primary partner. However,
private treatment clients were more likely to report unpro-
tected sex (see Table 1) and having had sex with an injec-
tion drug user (see Table 1) in the past year than their
public treatment counterparts. Public treatment enrollees
were more likely than private treatment clients to endorse
recent selling or trading sex for money, drugs or gifts
(27.4% vs. 13.4%, see Table 1).
Private treatment clients were more likely than public
treatment clients to have injected drugs in the year before
entering treatment, to have injected a prescription medica-
tion in the last 90 days before treatment, and to have
ingested prescription pills through higher risk snorting or
smoking routes (see Table 1).
Although private treatment clients reported higher
injection-related HIV risk behaviors in the analyses, on
average they had previously been tested for HIV fewer
times than public treatment clients (4.4 vs. 6.8 times,
T-Test: df = 375; t = −3.43, p < 0.01). In addition, the
availability and uptake of HIV treatment in substance treat-
ment facilities was less prevalent for private treatment
clients. Public treatment clients were more likely to have
HIV testing available through their treatment facility than
private clients (95.7% vs. 79.1%, see Table 1). Of those who
reported HIV testing was available at their facilities, public
treatment clients were also more likely to have been
offered the testing than were private clients (75.1% vs.
55.7%, see Table 1), and among those who had HIV testing
available at their treatment facilities, public treatmentclients were more likely to participate in testing (60.6%
vs. 24.3%, see Table 1).
Discussion
In this diverse sample of public and private NMUPD
treatment clients, our findings reveal several demographic
and socio-economic differences between the two treat-
ment groups. Significant associations with public treatment
type were Latino or Black/African-American ethnicity, and
having a lower income. These data correspond to recent
statistics that suggest Blacks/African-Americans and
Hispanic/Latinos have lower median household incomes
and are less likely to have health insurance coverage than
non-Hispanic Whites [42]. Our findings are generally con-
sistent with prior research in the area of health disparities,
including greater unmet need for substance abuse treat-
ment among African Americans and Latinos relative to
Whites due to a lack of financial resources [43]. Import-
antly, prior research has also shown that Whites are more
likely to access substance abuse treatment in specialty
facilities compared to racial and ethnic minorities [44].
While all of the programs studied here were specialized
substance abuse treatment centers, the private programs
tended to be smaller in size, with lower staff/client ratios,
which likely confers an advantage to these clients in terms
of a personalized and focused treatment experience. Al-
though the examination of treatment outcomes was
beyond the scope of the present study, our findings
nevertheless highlight substantial race/ethnic disparities
in access to private substance abuse treatment.
Our results showed that public treatment clients were
more likely to be users of crack cocaine than were pri-
vate treatment clients. Given their lower overall income
levels, drug of choice may have been influenced by so-
cioeconomic factors. Prior research has indicated that
crack cocaine use tends to be clustered among lower so-
cioeconomic status communities due to its lower costs as
compared to other substances such as cocaine [45,46]. In
addition, public treatment clients are also more likely to
have traded or sold sex (see Table 1). This is likely driven
by this elevated prevalence of crack cocaine among public
participants, which has long been associated with transac-
tional sex and survival sex work [25,47].
Benzodiazepine users were 3.49 times more likely to
be in public treatment as compared to opioid users (see
Table 1). We speculate that this finding is tied to the
higher prevalence of cocaine use among the public treat-
ment group, as benzodiazepines are reportedly used to
come down from stimulants or moderate cocaine with-
drawal [48].
Significant associations with private treatment enroll-
ment were younger age, non-Hispanic White ethnicity,
having a high school education and having medical
insurance. Private facility clients were 2.44 times more
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likely to have primary prescription opioid misuse. This is
not surprising as the two are frequently substituted [49].
It is not unexpected that medical insurance coverage
and higher income were associated with private treat-
ment enrollment, given that enrollment in these facilities
is based on ability to pay. Similarly, the younger age as-
sociation with private treatment might also reflect access
to parents’ financial resources, and may have been influ-
enced by the Patient Protection and Affordable Care Act
of 2010, which extended parents’ insurance health care
coverage to their children under the age of 26 [50].
In addition to differences in demographics and sub-
stance use profiles, the treatment groups also differed in
patterns of HIV risk behavior in the analyses, including
route of drug administration and sexual risk behaviors.
Although HIV risk behaviors were clearly present in
both samples, private treatment clients reported higher
levels of several recent risk behaviors in bivariate regres-
sions than public treatment clients, including injection
drug use. Because private treatment clients had higher
income and resources, our findings appear to diverge
from recent research suggesting that transition to injec-
tion drug use is economically motivated as a cheaper
route of administration [18].
In addition to these differences in risk behaviors, the
availability, accessibility and uptake of HIV testing ser-
vices were reported less frequently by private as opposed
to public treatment clients. The higher prevalence of
several sexual and needle risk behaviors among private
treatment participants is particularly worrisome as they
reported fewer prior HIV tests. This resonates with other
studies that have documented a higher prevalence of pre-
vention services (such as sexually transmitted infection
testing) in public as compared to private substance treat-
ment facilities [30,51]. One recent nationwide study do-
cumented that only 27% of private treatment facilities
offered HIV testing [52].
Strengths
This study included large and diverse samples of public
and private substance abuse treatment clients. Compari-
sons of HIV risk behaviors between the two groups are
not apparent in prior studies. Other strengths include the
focus on NMPDUs, who are underrepresented in the lit-
erature and comprise a growing proportion of new treat-
ment admissions. As well, the data were collected using a
comprehensive assessment of nonmedical prescription
drug use, including both opioids and benzodiazepines.
Limitations
There are several limitations to this study. First, the re-
sults may not be generalizable to larger populations of
NMPDUs, as this study was conducted in South Floridaand included non-probability samples. In addition, we
used a cross sectional design, and as such causal links
cannot be established. Further, substance use, sexual
behaviors, and HIV status were self-reported data, and
may be susceptible to social desirability and/or recall
bias. However, these concerns are reduced given the
high levels of reports of these behaviors.
Conclusions
The public and private treatment samples that were in-
cluded in this study had differing demographics and
substance use patterns. HIV risks appeared substantial
in both groups, and HIV testing was not easily available
to many of the clients in the substance treatment cen-
ters. As such, HIV testing should be implemented more
universally, and tailored HIV interventions should be
introduced.
The CDC recommends that all substance abuse treat-
ment clients receive routine HIV testing that is not con-
tingent on their individual risk factors [53]. Routine
testing reaches a broader base of patients as all individ-
uals are tested unless they decline [54]. The value of
HIV testing in substance abuse treatment includes its
cost effectiveness [53,54] and a likely reduction in risky
sexual behaviors after a positive test [55], which could
lead to reductions in HIV transmission. In addition to
the benefit of reduced HIV transmission, routine HIV
testing can lead to quicker linkages with HIV care [53].
Despite these benefits, only a minority of states require
HIV testing services to be provided during substance
abuse treatment. In those states requiring testing avail-
ability, it is usually mandatory only in facilities receiving
state funding [56]. In this study, we found that the
CDC’s recommendations [53] failed to be fully imple-
mented as many participants, particularly the private
treatment clients, were not offered routine HIV testing
while in treatment. Both groups of participants had sub-
stantial risk factors for HIV and would benefit from the
routine testing procedures.
Although HIV testing recommendations include the
universal availability to substance treatment clients, our
study also points to the need for HIV sexual risk interven-
tions that are tailored to the needs of the clients being
served. This is important as the samples of private and
public treatment clients differed on both demographic and
HIV risk factors. Sexual risk reduction interventions dur-
ing substance abuse treatment appear to be less consist-
ently successful than interventions to reduce needle risk
behaviors [34]. However, such interventions can be effica-
cious if they are carefully designed. Several studies in treat-
ment settings that implemented interventions ranging
from two to five sessions of HIV education and behavioral
skills building were associated with significant reductions
in HIV sexual risk behaviors [31,57].
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duction interventions are provided in substance abuse
treatment facilities, nor how frequently these programs
implement evidence-based and carefully designed sessions.
A majority of substance treatment facilities in Florida
report that they offer such sessions [58], including the
treatment centers that participated in this study. However,
this does not necessarily indicate the frequency, adherence
or attendance of the sessions [56], or whether these inter-
ventions are effective among NMPDUs populations.
Understanding the HIV risk profiles of NMUPD treat-
ment enrollees is crucial as their prevalence in treatment
settings continues to increase. As best treatment practices
for nonmedical use of prescription drugs have not yet
been developed [2], this is an ideal time to implement uni-
versal HIV testing and population specific educational
protocols in substance abuse treatment facilities. This
would be particularly beneficial in private substance
abuse treatment facilities, where HIV prevention is
apparently lacking.
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